ABSTRACT

The present invention provides fused heterocyclic derivatives represented by the general formula:



(I)

wherein R^1 represents H, halogen, OH, etc.; R^2 represents H, halogen or an alkyl group; R^3 and R^4 represent H, OH, halogen, etc.; Q represents alkylene, etc.; ring A represents aryl or heteroaryl; and G represents



(G 1)

or



(G 2)

, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.